{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:37Z","timestamp":1707524497921},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,15]]},"DOI":"10.7759\/cureus.20433","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T13:40:26Z","timestamp":1639575626000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Severe Bullous Dermatitis With Mixed Bullous Pemphigoid and Pemphigus Vulgaris Cutaneous Manifestations"],"prefix":"10.7759","author":[{"given":"Reece D","family":"Burns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Develyn","family":"Vetos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Muraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20199011","article-title":"Pemphigus vulgaris","volume":"94","author":"Porro AM","year":"2019","unstructured":"Porro AM, Seque CA, Ferreira MC, Enokihara MM. Pemphigus vulgaris. An Bras Dermatol. 2019, 94:264-78. 10.1590\/abd1806-4841.20199011","journal-title":"An Bras Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto D","year":"2019","unstructured":"Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. An Bras Dermatol. 2019, 94:133-46. 10.1590\/abd1806-4841.20199007","journal-title":"An Bras Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4390","article-title":"Assessment of diagnostic strategy for early recognition of bullous and nonbullous variants of pemphigoid","volume":"155","author":"Meijer JM","year":"2019","unstructured":"Meijer JM, Diercks GF, de Lang EW, Pas HH, Jonkman MF. Assessment of diagnostic strategy for early recognition of bullous and nonbullous variants of pemphigoid. JAMA Dermatol. 2019, 155:158-65. 10.1001\/jamadermatol.2018.4390","journal-title":"JAMA Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.009","article-title":"Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid","volume":"69","author":"S\u00e1rdy M","year":"2013","unstructured":"S\u00e1rdy M, Kostaki D, Varga R, Peris K, Ruzicka T. Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. J Am Acad Dermatol. 2013, 69:748-53. 10.1016\/j.jaad.2013.07.009","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly P","year":"2002","unstructured":"Joly P, Roujeau JC, Benichou J, et al.. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002, 346:321-7. 10.1056\/NEJMoa011592","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams HC","year":"2017","unstructured":"Williams HC, Wojnarowska F, Kirtschig G, et al.. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017, 389:1630-8. 10.1016\/S0140-6736(17)30560-3","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.5.612","article-title":"A retrospective analysis of patients with bullous pemphigoid treated with methotrexate","volume":"144","author":"Kjellman P","year":"2008","unstructured":"Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008, 144:612-6. 10.1001\/archderm.144.5.612","journal-title":"Arch Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.2.174","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid","volume":"136","author":"Schmidt E","year":"2000","unstructured":"Schmidt E, Obe K, Br\u00f6cker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000, 136:174-8. 10.1001\/archderm.136.2.174","journal-title":"Arch Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer N","year":"2019","unstructured":"Kremer N, Snast I, Cohen ES, et al.. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019, 20:209-16. 10.1007\/s40257-018-0401-6","journal-title":"Am J Clin Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi C","year":"2007","unstructured":"Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al.. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007, 57:622-8. 10.1016\/j.jaad.2007.05.024","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.91","article-title":"Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial","volume":"130","author":"Beissert S","year":"2010","unstructured":"Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010, 130:2041-8. 10.1038\/jid.2010.91","journal-title":"J Invest Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.11.1447","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus","volume":"142","author":"Beissert S","year":"2006","unstructured":"Beissert S, Werfel T, Frieling U, et al.. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006, 142:1447-54. 10.1001\/archderm.142.11.1447","journal-title":"Arch Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.04.039","article-title":"A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus","volume":"64","author":"Martin LK","year":"2011","unstructured":"Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011, 64:903-8. 10.1016\/j.jaad.2010.04.039","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.192","article-title":"B-cell-directed therapy for inflammatory skin diseases","volume":"129","author":"Nagel A","year":"2009","unstructured":"Nagel A, Hertl M, Eming R. B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol. 2009, 129:289-301. 10.1038\/jid.2008.192","journal-title":"J Invest Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in severe pemphigus","volume":"1173","author":"Schmidt E","year":"2009","unstructured":"Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci. 2009, 1173:683-91. 10.1111\/j.1749-6632.2009.04744.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl M","year":"2008","unstructured":"Hertl M, Zillikens D, Borradori L, et al.. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008, 6:366-73. 10.1111\/j.1610-0387.2007.06602.x","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref17","article-title":"Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update","volume":"15","author":"Arin MJ","year":"2005","unstructured":"Arin MJ, Hunzelmann N. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update. Eur J Dermatol. 2005, 15:224-30.","journal-title":"Eur J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly P","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al.. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017, 389:2031-40. 10.1016\/S0140-6736(17)30070-3","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2011.606452","article-title":"Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update","volume":"45","author":"Czernik A","year":"2012","unstructured":"Czernik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity. 2012, 45:111-8. 10.3109\/08916934.2011.606452","journal-title":"Autoimmunity"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/79806-a-case-of-severe-bullous-dermatitis-with-mixed-bullous-pemphigoid-and-pemphigus-vulgaris-cutaneous-manifestations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:52Z","timestamp":1707507232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/79806-a-case-of-severe-bullous-dermatitis-with-mixed-bullous-pemphigoid-and-pemphigus-vulgaris-cutaneous-manifestations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.20433","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,15]]}}}